A Double-blind Randomized, Placebo-controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers.
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs TAK 003 (Primary) ; TAK 003 (Primary)
- Indications Dengue
- Focus Adverse reactions
- 21 Feb 2012 Status changed from active, no longer recruiting to completed, according to the Inviragen website.
- 21 Feb 2012 Planned initiation date changed to 1 May 2010, according to ClinicalTrials.gov.
- 21 Jul 2011 Planned end date changed from 1 Aug 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.